anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vascular complications due to diabetes mellitus (DM) are the result of sustained vascular injury with insufficient vascular repair. In chronic diabetes, vascular reparative mechanism can be lost resulting in development of microvascular complications (MVC), such as diabetic retinopathy (DR). We assessed the reparative function of progenitor cells that circulate in the peripheral blood of diabetic individuals and found that the vascular wall-derived progenitor cells, endothelial colony forming cells (ECFCs), were depleted in diabetics with MVC. Bone marrow-derived progenitor cells, CD45+CD34+ were dysfunctional in diabetics with MVC. We found that human inducible pluripotent stem cells (hiPSCs)-derived ECFCs displayed the ability to form functional and durable blood vessels in vivo and conferred therapeutic revascularization by connecting with and remaining integrated with host rodent vessels long term. We characterized a mesoderm subset (SSEA5-KNA+ cells) generated from hiPSCs that gives rise to ECFCs. Finally, we used hiPSCs to generate CD34+CD45+ cells and tested the impact of co-administration of these cells with ECFCs within the vitreous. The addition of CD34+CD45+ cells with ECFCs resulted in the enhanced survival, function and reparative ability of the ECFCs. This beneficial effect was mediated by reducing retinal oxidative stress and inflammation.

These novel and paradigm shifting findings led us to hypothesize: the hiPSC-derived-mesoderm subset (SSEA5-KNA+) can be utilized for long term revascularization of vasodegenerative capillaries and their reparative action can be further enhanced by coinjection of CD34+CD45+ cells that provide anti-oxidant and anti-inflammatory effects.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and concerns treating purulent rhinosinusitis. The method involves genetic typing by allelic polymorphism of interleukin-1 cytokine gene signs. The therapy is conducted if observing low-producing allele homozygous gene IL-1RA "1/1" in a patient. Following irrigation of the paranasal sinuses with isotonic solution is the introduction of the preparation of recombinant IL - 1RA in dosage 1.0 mg dissolved in 1.0-1.5 ml of isotonic solution in the paranasal sinuses. The introduction is conducted daily until purulence disappears. ^ EFFECT: method improves efficacy of the cytokine therapy of the patients with purulent rhinosinusitis by reducing length of treatment. ^ 3 ex
Compounds which bind to selectin receptors and thus may modulate the course of inflammation, cancer and related processes by intervening with cell-cell adhesion events. Further, such compounds can be used for identification and analysis of such receptors. In this regard the invention is directed to compounds of formula (I). wherein R1 is independently H, alkyl, aryl, an aryl alkyl, alkenyl or one or more additional saccharide residues; R2=H or OH provided that when R2 is H, R3 is OH; R3=H or OH provided that when R3 is H, R2 is OH; X=H, SO3- or PO4-; Y is independently H, OH, OR4 or NHCOR4, wherein R4 is alkyl, and Z is an organic acid residue.  alpha -L-Fucose residue can be modified or replaced with suitable bioisosters or a different saccharide residue such as D-mannose. Modification of L-fucose may include replacement of each or all of the hydroxyl groups with H or OR' wherein R' can be methyl, ethyl or allyl groups.
Intraventricular hemorrhage and post-hemorrhagic hydrocephalus remain a leading cause of mortality and long-term morbidity in premature infants. The two most common temporary cerebrospinal fluid (CSF) diversion procedures are the ventriculosubgaleal shunt (SGS) and an implanted ventricular reservoir (RES) for intermittent CSF removal. These methods are physiologically very different and their comparative effectiveness in treating hydrocephalus and possibly reducing the need for an eventual permanent CSF shunt is currently not known. The goal of this pilot study is to obtain information critical for planning and executing a future randomized trial comparing SGS and RES. Specifically, this pilot study will establish inclusion criteria, define the primary outcome, and standardize the interventions in preparation for initiating a comparative trial between the SGS and RES procedures. In addition, the importance of examining the neurodevelopmental outcomes for these patients has been recognized within the neurosurgical and neuropsychological settings. Therefore, the scope of this study has been extended to include an examination of the neurodevelopmental outcomes at 18 to 22 months and at 36 to 42 months in patients who undergo BSID-III testing at their clinical centers.
The invention relates to an acute dysentery healing drug for lambs. The acute dysentery healing drug comprises radix isatidis, astragalus membranaceus, fructus aurantii immaturus, rheum officinale, mangnolia officinalis, dark plum, medicated leaven, Chinese yam, sesame, dandelion and rhizoma alismatis. A finished product is prepared by the following steps: weighing the above ingredients, washing and airing, grinding into powders and interblending, decocting with water, and successively adding sodium chloride, potassium chloride and glucose. In early stage of the disease, the drug is continuously taken for 2 days, twice a day and 30ml for each time. After symptom alleviates, the drug is continuously taken for one day, twice a day and 20 ml for each time. After normal medication, acute dysentery can be effectively cured, and physique of lambs also can be enhanced to rapidly recover their physique.
The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced  in vivo  by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. 
     The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.

The safety of Monoferric was evaluated in 3008 patients with iron deficiency anemia enrolled in two randomized, actively-controlled trials. Trial 1 enrolled adult patients with iron deficiency anemia with intolerance to oral iron or had an unsatisfactory response to oral iron with a clinical need for repletion of iron stores. Eligible subjects were required to have a baseline hemoglobin of ≤11g/dl, transferrin saturation (TSAT) of less than 20% and serum ferritin level of <100 ng/mL. Trial 2 enrolled adult patients with non-dialysis dependent chronic kidney disease (CKD) with iron deficiency anemia ( see Clinical Studies (14)). Eligible subjects also had to have serum ferritin ≤100 ng/mL or ≤300 ng/mL if TSAT ≤30%. 

Trial 1 and Trial 2

In the two randomized, actively-controlled clinical trials, Trial 1 and Trial 2 (see Clinical Studies (14)) , patients were randomized in a 2:1 ratio to intravenous Monoferric (n = 2008) or intravenous iron sucrose (n = 1000) respectively. Monoferric was administered as a single intravenous infusion of 1000 mg diluted in 100 mL 0.9 % sodium chloride and given over approximately 20 minutes (approximately 50 mg iron/min). Iron sucrose was administered as 200 mg undiluted intravenous injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times (1000 mg) within the first two weeks starting at baseline. 

The data described below reflect exposure to Monoferric in 2008 patients exposed to a 1000 mg single intravenous dose of Monoferric. The mean cumulative intravenous Iron exposure was 984 mg.

Trial 1 included 1483 patients with iron deficiency anemia in the safety analysis that had intolerance to oral iron or have had unsatisfactory response to oral iron or with a clinical need for rapid repletion of iron stores. Trial 2 included 1525 patients in the safety analysis who had non-dialysis dependent CKD. The mean (SD) age of the combined study population was 56.4 (18.3) years. The majority of patients were women (75.7%).

Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferric.

Adverse reactions related to treatment and reported by ≥1% of the treated patients in the combined analysis of Trial 1 and 2 are listed in Table 1.

Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferric group.

Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferric-treated patients in Trials 1 & 2.
Diet and lifestyle modifications remain the foundation of obesity treatment, but they have historically proven insufficient for significant, long-term weight loss. As a result, there is a high demand for new pharmacologic treatments to promote weight loss and prevent life-threatening diseases associated with obesity. Researchers are particularly interested in 1 type of drug, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), because of its promising potential in addressing the limitations of non-pharmacologic treatments. In addition to their role in weight loss, these drugs have shown promising early evidence of cardiovascular benefits in obese patients, further enhancing their clinical relevance. Semaglutide and liraglutide, which were initially approved for the treatment of type 2 diabetes, have since been approved by the Food and Drug Administration as weight loss medications due to their effectiveness in promoting significant and sustained weight loss. In this narrative review, we will explore the mechanism of GLP-1 RAs, their effects on weight loss, cardiovascular risk factors and outcomes, common adverse effects, and strategies for managing these effects.
Tenofovir DF: Tenofovir and TDF administered in toxicology studies to rats, dogs, and monkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed in humans caused bone toxicity. In monkeys the bone toxicity was diagnosed as osteomalacia. Osteomalacia observed in monkeys appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the bone toxicity manifested as reduced bone mineral density. The mechanism(s) underlying bone toxicity is unknown.

Evidence of renal toxicity was noted in 4 animal species. Increases in serum creatinine, BUN, glycosuria, proteinuria, phosphaturia, and/or calciuria and decreases in serum phosphate were observed to varying degrees in these animals. These toxicities were noted at exposures (based on AUCs) 2–20 times higher than those observed in humans. The relationship of the renal abnormalities, particularly the phosphaturia, to the bone toxicity is not known.
The invention discloses an antidepressant traditional Chinese medicine composition for warmly invigorating kidney yang as well as a preparation method and application thereof. The traditional Chinese medicine composition mainly comprises a plurality of parts by weight of curculigo rhizome and a plurality of parts by weight of herb of korean epimedium in a weight ratio of (1:1.5)-(1:3.0). The antidepressant traditional Chinese medicine composition also comprises a pharmaceutically acceptable auxiliary material. A dressing or an excipient comprises a solvent, a disintegrating agent, a correctant, a preservative and a colorant. The antidepressant traditional Chinese medicine composition can be prepared into clinically acceptable dosage forms including tablets, capsules, pills, particles, suspension agents, drop pills, oral liquid preparations, injections, aerosols and suppositories. The preparation method of the antidepressant traditional Chinese medicine composition for warmly invigorating kidney yang comprises a step of adopting water extraction or alcohol extraction preferably water extraction. The antidepressant traditional Chinese medicine composition for warmly invigorating kidney yang can be used for preventing or treating depression, and is suitable for depression patients with yang energy closing, yang depression mental deterioration, low spirit, slow thinking, laziness in speaking an less movement and sagged spirits.
The purpose of the present study is to examine the occupancy of brain β2-containing nicotinic acetylcholine receptors (β2-nAChR) by nicotine both at baseline and following administration of a nicotine vaccine. The number of brain β2-nAChR and the amount of nicotine occupancy both before and after vaccination will be measured using the nicotinic agonist \[123I\]5-IA-85380 (\[123I\]5-IA) and single photon emission computed tomography (SPECT). \[123I\]5-IA will be administered using the bolus plus constant infusion paradigm to smokers abstinent for 4-9 days (time period necessary for nicotine and pharmacological active metabolites to clear from brain). Three baseline SPECT images will be obtained after equilibrium has been reached (\~6 hours into the \[123I\]5-IA infusion). Then, IV nicotine will be administered (0.5-1.5 mg/70 kg will be infused over 10 minutes). Following a series of 4 nicotine vaccine shots, the same procedure will be repeated for a second \[123I\]5-IA scan day. We hypothesize that occupancy of β2-nAChR will be significantly lower, and take longer to plateau, following nicotine vaccine administration.
Methods are provided for reducing the number of HIV-infected cells or HIV infection-susceptible cells of a host. Therapeutically this is achieved by exposing the cells to a V region selective element (VRSE) which binds to T cell receptors (TCR) of a V region defined family (VRDF) that is preferentially infected with HIV. The therapeutic VRSE can be an antibody which binds to the VRDF and is capable of causing cytotoxicity of infected and infection-susceptible cells, either alone, in conjunction with host factors, or fused to a toxin. The number of HIV-infection susceptible cells can be reduced prophylactically and in some circumstances therapeutically by immunization with an antibody or T cell receptor that induces an immune response that includes antibodies that bind to the TCR of a VRDF associated with HIV infection. The latter antibodies inhibit the viability of the infected or infection-susceptible cell. Means for diagnosing and treating diseases in which there is biasing of the immune repertoire are also provided, including those circumstances where very little may be known about the causative agent or the mechanism of pathogenesis. This is accomplished by selecting monoclonal antibodies for detecting antibody repertoire changes characteristic of a disease, thereby providing a diagnosis, and perturbing the immune system repertoire in the opposite direction to the direction of skewing that is characteristic of the disease or condition, thereby providing a means of prophylaxis or therapy.
Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 Week cycle in combination with capecitabine administered orally at 650 mg/m\^2 twice daily (Day 1 to 21). Cycle length was 3 weeks with 3 weeks of capecitabine treatment without interruptions. Participants received the same regimen until unacceptable toxicity, PD, or participant withdrawal.
KYZATREX™ is not a 17-alpha-alkyl androgen and is not known to cause hepatic adverse effects. However, prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas. Patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue KYZATREX™ while the cause is evaluated.
In this study, the multifaceted toxicity induced by high doses of the essential trace element molybdenum in Allium cepa L. was investigated. Germination, root elongation, weight gain, mitotic index (MI), micronucleus (MN), chromosomal abnormalities (CAs), Comet assay, malondialdehyde (MDA), proline, superoxide dismutase (SOD), catalase (CAT) and anatomical parameters were used as biomarkers of toxicity. In addition, detailed correlation and PCA analyzes were performed for all parameters discussed. On the other hand, this study focused on the development of a two hidden layer deep neural network (DNN) using Matlab. Four experimental groups were designed: control group bulbs were germinated in tap water and application group bulbs were germinated with 1000, 2000 and 4000 mg/L doses of molybdenum for 72 h. After germination, root tips were collected and prepared for analysis. As a result, molybdenum exposure caused a dose-dependent decrease (p < 0.05) in the investigated physiological parameter values, and an increase (p < 0.05) in the cytogenetic (except MI) and biochemical parameter values. Molybdenum exposure induced different types of CAs and various anatomical damages in root meristem cells. Comet assay results showed that the severity of DNA damage increased depending on the increasing molybdenum dose. Detailed correlation and PCA analysis results determined significant positive and negative interactions between the investigated parameters and confirmed the relationships of these parameters with molybdenum doses. It has been found that the DNN model is in close agreement with the actual data showing the accuracy of the predictions. MAE, MAPE, RMSE and R2 were used to evaluate the effectiveness of the DNN model. Collective analysis of these metrics showed that the DNN model performed well. As a result, it has been determined once again that high doses of molybdenum cause multiple toxicity in A. cepa and the Allium test is a reliable universal test for determining this toxicity. Therefore, periodic measurement of molybdenum levels in agricultural soils should be the first priority in preventing molybdenum toxicity.
PURPOSE: A method for sterilizing a skin tissue-processed product is provided to minimize damage of skin tissues and to maintain form and function of skin tissue elements including protein/collagen. CONSTITUTION: A method for sterilizing a skin tissue-processed product comprises: a step of storing the skin tissue-processed product in vitamin C, vitamin C derivatives, or mixture of vitamin C and vitamin C derivatives and packaging; and a step of irradiating the skin tissue-processed product by gamma ray. The gamma ray is 5-30 kGy. The raw material of the skin tissue-processed product is human or animal-derived skin. The vitamin C derivatives are AA-2G, AA-2S, or AA-2P. The skin tissue-processed product is skin graft material or dressing.
PURPOSE:To obtain the subject allergen useful as the therapeutic agent for allergic diseases caused by acarian allergen by employing a gene coding a modified Der-fII produced by substituting a specific amino acid residue of an acarian main allergen Der-fII with alanine. CONSTITUTION:A procaryote or eucaryote is transformed with a replicated vector containing a gene coding a modified Der-fII, and subsequently cultured. A modified acarian main allergen is collected from the culture product. The modified acarian main allergen lowers the IgE antibody-binding activity, and inhibits wild type Der-fII binding to the IgE antibody. The modified Der-fII is produced by substituting alanine for one of the No.4, 6, 7, 10, 11, 12, and 127 amino acids of acarian main allergen Der-fII. A gene coding the acarian main allergen Der-fII has a DNA sequence of the formula, etc.
BACKGROUND: Immune cell dysfunction plays a central role in sepsis-induced immunoparalysis. Targeted treatment using healthy donor immune cell transfusions, particularly granulocyte concentrates (GC) potentially induces tissue damage. Initial trials using GC in an extracorporeal immune cell perfusion system provided evidence for beneficial effects with fewer side effects, by separating patient and donor immune cell compartments. A multicenter clinical trial is exploring feasibility and effects of a 6-h treatment (NCT06143137). This ex vivo study examines technical feasibility and cellular effects of an extended treatment interval up to 24 h.
METHODS: Standard GC were purified to increase the potential storage time and subsequently implemented in the extracorporeal immune cell perfusion system. Parameters assessed included cell viability, phagocytosis activity, oxidative burst, cytokine release, and metabolic parameters of purified. GC during an extended circulation time of up to 24 h.
RESULTS: After storage of 72 h granulocytes were viable throughout the study period and exhibited preserved functionality and metabolic activity. The findings highlight a time-dependent nature of cytokine release by neutrophils in the extracorporeal circuit, as cytokine secretion patterns showed IL-8 peaking within 6 h, while MCP-1, IL-6, IL-1β, and TNF-α increased after 24 h of circulation.
CONCLUSION: Purified GC remain functional after 72 h of storage and additional 24 h in the circulating treatment model. Cytokine secretion patterns revealed a significant increase, especially between 10 and 24 h of treatment. Extending treatment time holds promise for enhancing immune response against sepsis-induced immunoparalysis. These findings provide valuable insights for optimizing immune-targeted therapeutic interventions.
Systems, methods, and compositions produce crosslinking activity for treating ocular conditions. Various agents, additives, buffers, etc. may be used in the formulation with the cross-linking agent to enhance the treatment. For example, a composition for applying therapy to the cornea of an eye comprises a crosslinking agent that generates crosslinking activity in the cornea in response to exposure to photoactivating light. The composition further comprises an iron additive and a citrate buffer. In some cases, the cross-linking agent may include riboflavin. In other cases, the iron additive may include FeSO 4 . In further cases, the iron additive may be dissolved in the citrate buffer.
PURPOSE: To prevent emergency of closing a discharge pressure reducing mechanism or a discharge catheter by applying a hollow fiber capillary tube placed at the end of the discharge outlet of the first chamber as a filter. CONSTITUTION: An injector is put in a ring 10 after having determined an injection point using a template placed on human body. Next a dosage of medicine is injected in a chamber 9, then directly administered therefrom to the body through the discharge catheter 8. As the flow resistance generated in a pressure reducing mechanism is huge, the medicine is not allowed to be pressed backward to the first chamber 4 that is an inserting device. The device 1 is composed of another filter device in the shape of a hollow fiber capillary tube 15. A top of the tube 15 is connected to a discharge end of the discharge pressure redusing mechanism and conducted to the inside of the first chamber 4 through a discharge opening 6.  By placing the channel 16 in the chamber 4 on a diaphragm 3, it is made possible to insert it in the part of the hollow fiber capillary tube 15 conducted in the first chamber 4. Placing of the channel 16 on the diaphragm 3 is made not to accidentally close the hollow fiber capillary tube 15 placed in the first chamber 4 when the dosage comes fewer.